--- title: "Elevating Precision Dosing for Hemodialysis Patients: A New Vancomycin CRRT Model" description: InsightRX launches a new vancomycin CRRT model, enhancing precision dosing for hemodialysis patients, and sets a new standard in individualized medicine. image: https://blog.insight-rx.com/hubfs/Blog%20Generic%20Product%20Innovation.png --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://blog.insight-rx.com/) - For Providers - Solutions - [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd) - [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future) - Products - [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova) - [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo) - [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules) - [For Life Sciences](https://www.insight-rx.com/life-sciences) - Overview - [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences) - Products - [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova) - [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra) - Platform - [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning) - [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support) - Resources - Science - [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science) - [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications) - [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova) - Explore - [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories) - [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers) - [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software) - [Blog](https://blog.insight-rx.com/resources) - [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources) - [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership) - Company - About - [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about) - [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership) - [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board) - [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers) - [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers) - Press - [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases) - [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) Product Innovation # Elevating Precision Dosing for Hemodialysis Patients: A New Vancomycin CRRT Model - Published July 16, 2025 By [Dominic Tong](https://blog.insight-rx.com/resources/author/dominic-tong) ![](https://blog.insight-rx.com/hubfs/Blog%20Generic%20Product%20Innovation.png) At InsightRX, we are dedicated to advancing the science of individualized medicine. [Special patient populations](https://blog.insight-rx.com/resources/how-clinical-decision-support-precision-dosingcan-enhance-healthcare-equity-inclusion) like obese, elderly, pregnant, or critically ill patients, are often opportunities to improve population pharmacokinetic (popPK) models for clinical decision-making. To that end, our team is pleased to announce the launch of a newly developed vancomycin model for adult patients undergoing continuous renal replacement therapy (CRRT) within InsightRX Nova — a significant advancement for a group long underserved by existing pharmacokinetic tools. Using a data set of nearly 900 adult CRRT patients receiving vancomycin across 83 clinical sites, [our Data Science team evaluated](https://www.page-meeting.org/default.asp?abstract=11703) current population PK models and identified critical gaps in both predictive accuracy and clinical usability. By leveraging InsightRX’s [continuous learning framework](https://blog.insight-rx.com/resources/continuous-learning-model-informed-precision-dosing-pediatric-vancomycin), we developed and validated a new two-compartment popPK model on nearly 2,500 patients (with CRRT and non-CRRT patients), which was optimized to deliver precise vancomycin dosing assessments by using broadly available covariates such as fat-free mass, serum creatinine, and age. These variables are routinely collected in clinical care, which makes this model easier to use than some other hemodialysis models. ![performance-by-CRRT-model](https://blog.insight-rx.com/hs-fs/hubfs/performance-by-CRRT-model.png?width=600&height=375&name=performance-by-CRRT-model.png) The newly developed model outperforms all other published CRRT models, including the Bae, Hui, Ghouti-Terki (GT), and modified Goti (mG) models, on a hold-out data set of 263 patients and marks a meaningful step forward for clinicians caring for patients on hemodialysis. We've also already included it in an update to our marquee [InsightRX Gemini model auto-select feature](https://blog.insight-rx.com/resources/introduction-to-insightrx-gemini-patient-model-selection), meaning clinical decision support for patients on renal replacement therapy is that much easier. Following this extensive evaluation, InsightRX now recommends the new Tong CRRT model as the default for dosing vancomycin in adult patients receiving continuous renal replacement therapy. Want to learn more? Read the full analysis below! [![Read the Analysis](https://no-cache.hubspot.com/cta/default/40041574/interactive-192780579995.png)](https://blog.insight-rx.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKd5wXehPpDmghdNe8J%2BaQQ%2FK6ZBXkHwTmX42ZfHSk2%2B1OmmkNsNKkHHnV5b3b28ItCLmoo9bhHhCEWdmi6zmebWvTkJxsFNeNg9aSfJISj8gKBhCefGne3F0PGs%2BVMkeD67ZTnnfv3mTsxY7sDTorrNu2lcWGQ9fJB7d9%2FRUiwQ4N1cFNGHGv103sMxNo%3D&webInteractiveContentId=192780579995&portalId=40041574) [vancomycin](https://blog.insight-rx.com/resources/tag/vancomycin) [model selection](https://blog.insight-rx.com/resources/tag/model-selection) [data science](https://blog.insight-rx.com/resources/tag/data-science) #### On this page… About the author [Dominic Tong, PhD](https://blog.insight-rx.com/resources/author/dominic-tong) Principal Data Scientist **Connect with us to get the latest blog updates, instantly sent to your inbox** ## Dig deeper. Explore related articles and additional posts on the InsightRX blog. [Product Innovation Sep 5, 2025 New Continuous Learning PK Model Outperforms Published PopPK Models for Gentamicin](https://blog.insight-rx.com/resources/continuous-learning-approach-gentamicin-precision-dosing) [Product Innovation Jul 30, 2025 Improving Vancomycin Dosing in Pediatric Subpopulations (Part I): Guiding Model Selection in CVICU Patients](https://blog.insight-rx.com/resources/vancomycin-dosing-pediatrics-cvicu-model-selection) [Product Innovation Aug 8, 2025 Improving Vancomycin Dosing in Pediatric Subpopulations (Part II): Guiding Model Selection in Oncology Patients](https://blog.insight-rx.com/resources/vancomycin-dosing-pediatrics-oncology-model-selection) #### What We Do ##### For Providers - [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova) - [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo) - [Drug Modules](https://www.insight-rx.com/provider/drug-modules) ##### For Life Sciences - [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova) - [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra) - [Companion Applications](https://www.insight-rx.com/life-sciences/nova#companion-applications) #### How We Do It ##### Platform - [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning) - [Integrations](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support](https://www.insight-rx.com/platform/success-support) ##### Science - [Data Science](https://www.insight-rx.com/data-science) - [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications) #### Information ##### Resources - [Success Stories](https://www.insight-rx.com/success-stories) - [White Papers](https://www.insight-rx.com/white-papers) - [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software) - [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova) ##### Blog - [All Posts](https://blog.insight-rx.com/resources) - [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership) #### About - [Our Story](https://www.insight-rx.com/about) - [Leadership](https://www.insight-rx.com/leadership) - [Advisory Board](https://www.insight-rx.com/advisory-board) - [Our Customers](https://www.insight-rx.com/customers) - [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media](https://blog.insight-rx.com/press-releases?section=media) - [Careers](https://www.insight-rx.com/careers) - [Contact](https://www.insight-rx.com/contact-us) --- ![CE marking](https://blog.insight-rx.com/hubfs/ce-mark-white.svg) InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1. InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance. 740-05000-REC-01 · 08/2025 --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://www.insight-rx.com/) 548 Market Street #88083 San Francisco, CA 94104 --- © 2026 InsightRX, Inc. All rights reserved. [Privacy Policy](https://www.insight-rx.com/privacy-policy) Cookie Preferences ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Dominic Tong, PhD - Principal Data Scientist", "url" : "https://blog.insight-rx.com/resources/author/dominic-tong" }, "dateModified" : "2026-09-01T21:59:04.393Z", "datePublished" : "2025-07-16T20:18:41.000Z", "headline" : "Elevating Precision Dosing for Hemodialysis Patients: A New Vancomycin CRRT Model", "image" : [ "https://blog.insight-rx.com/hubfs/Blog%20Generic%20Product%20Innovation.png" ], "mainEntityOfPage" : { "@id" : "https://blog.insight-rx.com/resources/new-model-for-vancomycin-patients-on-hemodialysis-improves-predictive-performance", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.insight-rx.com/hubfs/insightrx_logo_color%20500%20x%20250-1.png" }, "name" : "InsightRX" } } ```